ClinicalTrials.gg

Program

ebronucimab

Also written as “AK102”, “Ebronucimab” and “450mg AK102”.

Its studies are mostly in Hyperlipidemias · Hypercholesterolemia · Homozygous Familial Hypercholesterolemia · Hyperlipoproteinemia Type II, led by Akeso.

Furthest: phase 3, since Feb 9, 202210 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akeso101 open or runningphase 3since Feb 9, 2022Apr 28, 2019none ahead

Also a collaborator on its studies: ad-pharmaceuticals-co-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 28, 2019First study: phase 2 study in Homozygous Familial HypercholesterolemiaFirst studyNCT03933293 · 10 enrolled · China
  2. Nov 17, 20192 phase 2 studiesNCT04173793, NCT04173403
  3. Nov 17, 2019Phase 1 study in HypercholesterolemiaNCT04169386 · 32 enrolled · China
  4. Apr 21, 2020Phase 2 study in HypercholesterolemiaNCT04358432 · 262 enrolled · China
  5. Feb 9, 20223 phase 3 studies in HyperlipidemiasNCT05260411, NCT05255458, NCT05255094
  6. Oct 12, 2024Phase 1 study in Healthy Subjects (HS)NCT06641388 · 180 planned · China
  7. Jun 20, 2025Phase 1 study in Healthy SubjectsNCT07043283 · 230 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07043283Healthy Subjects · China1CompletedFeb 7, 2026230
NCT06641388Healthy Subjects (HS) · China1Not yet recruitingApr 30, 2025180
NCT05260411Hyperlipidemias · China3CompletedDec 19, 2022246
NCT05255458Hyperlipidemias · China3CompletedJan 9, 2023122
NCT05255094Hyperlipidemias · China3CompletedJun 22, 2022464
NCT04358432Hypercholesterolemia · China2CompletedFeb 25, 2021262
NCT04173793Heterozygous Familial Hypercholesterolemia · China2CompletedSep 26, 2022109
NCT04173403Hypercholesterolemia · China2CompletedFeb 17, 2023796
NCT04169386Hypercholesterolemia · China1CompletedNov 22, 201832
NCT03933293Homozygous Familial Hypercholesterolemia · China2CompletedMar 15, 202110

How it is read

Names in the registry

  • “AK102”, 9 entries
  • “Ebronucimab”, 3 entries
  • “450mg AK102”, 1 entry
  • “300mg AK102”, 1 entry
  • “150mg AK102”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.